Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline

For early detection of Alzheimer's disease, it is important to find biomarkers with predictive value for disease progression and clinical manifestations, such as cognitive decline. Individuals can now be profiled based on their biomarker status for A beta 42 (A) or tau (T) deposition and neurodegeneration (N). The aim of this study was to compare the cerebrospinal fluid (CSF) and imaging (PET/MR) biomarkers in each ATN category and to assess their ability to predict longitudinal cognitive decline. A subset of 282 patients, who had had at the same time PET investigations with amyloid-beta and tau tracers, CSF sampling, and structural MRI (18% within 13 months), was selected from the ADNI dataset. The participants were grouped by clinical diagnosis at that time: cognitively normal, subjective memory concern, early or late mild cognitive impairment, or AD. Agreement between CSF (amyloid-beta-1-42(A), phosphorylated-Tau181(T), total-Tau(N)), and imaging (amyloid-beta PET (florbetaben and florbetapir)(A), tau PET (flortaucipir)(T), hippocampal volume (MRI)(N)) positivity in ATN was assessed with Cohen's Kappa. Linear mixed-effects models were used to predict decline in the episodic memory. There was moderate agreement between PET and CSF for A biomarkers (Kappa = 0.39-0.71), while only fair agreement for T biomarkers (Kappa <= 0.40, except AD) and discordance for N biomarkers across all groups (Kappa <= 0.14) was found. Baseline PET tau predicted longitudinal decline in episodic memory irrespective of CSF p-Tau181 positivity (p <= 0.02). Baseline PET tau and amyloid-beta predicted decline in episodic memory (p <= 0.0001), but isolated PET amyloid-beta did not. Isolated PET Tau positivity was only observed in 2 participants (0.71% of the sample). While results for amyloid-beta were similar using CSF or imaging, CSF and imaging results for tau and neurodegeneration were not interchangeable. PET tau positivity was superior to CSF p-Tau181 and PET amyloid-beta in predicting cognitive decline in the AD continuum within 3 years of follow-up.